DNA methylation of serotonin genes as predictive biomarkers of antidepressant treatment response

Silvia Elisabetta Portis Bruzzone,Brice Ozenne,Patrick MacDonald Fisher,Gabriela Ortega,Martin Balslev Jørgensen,Gitte Moos Knudsen,Klaus-Peter Lesch,Vibe Gedsoe Frokjaer
DOI: https://doi.org/10.1016/j.pnpbp.2024.111160
IF: 5.201
2024-10-05
Progress in Neuro-Psychopharmacology and Biological Psychiatry
Abstract:Selective serotonin reuptake inhibitors (SSRI) are frequently ineffective in treating depressive episodes and biomarkers are needed to optimize antidepressant treatment outcomes. DNA methylation levels of serotonin transporter ( SLC6A4 ) and tryptophan hydroxylase 2 genes ( TPH2 ) have been suggested to predict antidepressant clinical outcomes but their applicability remains uncertain. In this study, we: 1) evaluated SLC6A4 / TPH2 methylation biomarker potential for predicting clinical outcomes after escitalopram treatment; 2) evaluated whether changes in SLC6A4 / TPH2 methylation are informative of treatment mechanisms. We used a cohort of 90 unmedicated patients with major depressive disorder that were part of a 12-week open-label longitudinal trial and compared our observations with previous findings. Depressive symptoms were measured at baseline and after 8 and 12 weeks of treatment using the Hamilton Depression Rating Scale (HAMD 6/17 ). We found an association between baseline TPH2 methylation and both clinical response ( β :3.43; p = 0.01; 95 % CI:[0.80; 6.06]) and change in depressive symptoms after 8 weeks ( β :−45.44; p = 0.01; 95 %CI:[− −78.58; −12.30]). However, we found no evidence for predictive value of any gene ( TPH2 AUC: 0.74 95 % CI:[0.42;0.79]; SLC6A4: AUC: 0.61; 95 % CI: [0.48–0.78]). Methylation levels changed at the trend level for CpG sites of SLC6A4 and TPH2 over the course of 12 weeks of treatment. In addition, similar to previous observations, we found a trend for an association between methylation of SLC6A4 CpG2 (chr17:30,236,083) and HAMD 17 change after 12 weeks. Our findings suggest that although TPH2 and SLC6A4 methylation may be informative of antidepressant treatment outcome, they are unlikely to prove useful as clinical predictor tools.
pharmacology & pharmacy,neurosciences,psychiatry,clinical neurology
What problem does this paper attempt to address?